Crescent Biopharma
CBIO
28 hedge funds and large institutions have $114M invested in Crescent Biopharma in 2015 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 6 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
0% more funds holding
Funds holding: 28 → 28 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0.8% less ownership
Funds ownership: 73.17% → 72.36% (-0.8%)
50% less capital inflows, than outflows
Capital inflows: $1.05M | Capital outflows: $2.11M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$328K |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$158K |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$105K |
| 4 |
SIM
Spark Investment Management
New York
|
+$105K |
| 5 |
Morgan Stanley
New York
|
+$93.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MSA
Mason Street Advisors
Milwaukee,
Wisconsin
|
-$734K |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$658K |
| 3 |
JP Morgan Chase
New York
|
-$195K |
| 4 |
Goldman Sachs
New York
|
-$125K |
| 5 |
Blackstone Inc
New York
|
-$119K |
CBIO Hedge Fund Activity: Q1 2015 in Review
28 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q1 2015, worth a combined $114M — up 14% from $100M a quarter earlier.
Fund positioning in CBIO was balanced in Q1 2015: 6 funds opened new positions, 6 closed out, 10 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $328K. The largest seller was Mason Street Advisors, exiting entirely with an estimated $734K sold.
- 28 institutional investors held Crescent Biopharma (CBIO) as of Q1 2015, unchanged from Q4 2014.
- Funds reported $114M of Crescent Biopharma stock for Q1 2015, up 14% quarter-over-quarter.
- 6 funds opened new Crescent Biopharma positions in Q1 2015 and 6 closed out, a net change of 0 holders.
- The largest Crescent Biopharma buyer in Q1 2015 was Renaissance Technologies, an estimated $328K added.
- The largest Crescent Biopharma seller in Q1 2015 was Mason Street Advisors, an estimated $734K sold.
Based on aggregated 13F filings for Q1 2015.